Two Drugmakers Dominate Obesity Boom, Tiny Fund Holds Both
Two drugmakers lead the obesity drug surge, while a small fund owns both names at a fractional stake. This highlights...
During crashes, passive index funds typically deliver steadier exposure and lower fees, while active funds may outperform briefly but incur higher risks and costs.
24,770 articlesTwo drugmakers lead the obesity drug surge, while a small fund owns both names at a fractional stake. This highlights...
Intel's turnaround gains traction amid AI-driven demand and a narrowing foundry loss gap, fueling a debate about whet...
A quiet dividend king in the utility space could be the sleeper winner you’ve been waiting for. This article explains...
Fundstrat co-founder Tom Lee points to the ETH/BTC ratio as a sign of a potential leadership shift in crypto, suggest...
Jim Cramer says he cringes at owning AT&T or Verizon as Bernstein flags Starlink competition risk, signaling a potent...
A new Fidelity study finds that a 65-year-old today may incur about $172,500 in lifetime medical costs, excluding lon...
A Republican senator signals his support may hinge on Todd Blanche meeting Epstein accusers, turning the confirmation...
Copart director Daniel Englander recently sold 80,000 shares for about $2.2 million. With CPRT down roughly 40%, inve...
Palantir faces a pivotal investor update that could move the stock. This guide breaks down the risks, catalysts, and ...
A Berkshire-inspired ETF touts a 15% yield by layering a stock-picker approach with an option strategy and return of ...
Starboard Value is pressing Riot Platforms to accelerate its pivot into AI data centers, arguing Texas power assets c...
As markets stay choppy in early 2026, retirees turn to monthly dividend stocks for predictable income and capital pre...